Pamorelin La (Triptorelin)

Triptorelin, the active ingredient in Pamorelin La, is a gonadotropin-releasing hormone (GnRH) agonist presented as a sterile powder for subcutaneous injection use. It is employed in the management of hormone‑dependent conditions such as prostate cancer, endometriosis and central menopausal symptoms. GNH USA supplies Pamorelin La as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Pamorelin La as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamorelin La is a GnRH‑agonist that modulates the hypothalamic‑pituitary‑gonadal axis in several hormone‑sensitive diseases.

- Prostate cancer: provides androgen suppression to slow tumor growth. - Endometriosis: reduces ectopic endometrial tissue activity by lowering estrogen levels. - Central precocious puberty: delays further sexual development by suppressing gonadotropins. - Assisted reproductive technology (ART) protocols: controls ovarian stimulation timing. - Uterine fibroids: alleviates symptoms through estrogen suppression. - Transgender hormone therapy (male‑to‑female): facilitates estrogen‑dominant regimens by suppressing testosterone production.

Triptorelin may cause a range of adverse reactions, most of which are dose‑dependent and reversible after discontinuation.

Common Side Effects: - Hot‑spot ​​ ​ ​  ​  ​ ​ ​  ​  ​  ​  ​  :  fl     ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ -  head  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ - Injection site reactions: pain, erythema, or swelling. - Menopausal‑like symptoms: hot flashes, night sweats. - Headache. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction, stroke. - Severe allergic reactions: anaphylaxis. - Bone loss leading  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ​​ ​ ​ ​​ ​ ​ - Hormone‑dependent tumor   ​    ​ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​​ -  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - Pituitary‑axis ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - ​ ​​​​​ -  

Triptorelin  ​  ... ... ... ... ... ... ... ... …  ... ... ... ... ...